Project Grant R44DK138647
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$1M
Similar Awards
This Project Grant award of $340,822 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to determine the molecular and cellular mechanisms by which heparan sulfate controls parathyroid hormone-related protein (PTHrP) signaling via the PTH type 1 receptor (PTHR). The research aims to characterize the binding properties of PTHrP and heparin/heparan sulfate...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) provides $647,486 to Inlighta Biosciences LLC, a woman-owned small business located in Marietta, Georgia. The award supports research aimed at developing calcium-sensing receptor (CaSR) targeted theragnostic agents and imaging agents for polycystic kidney disease (PKD) and other CaSR-associated...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports the development of a novel therapeutic antibody for the treatment of acromegaly. Acromegaly is a rare endocrine disorder that leads to excess growth hormone production and serious health complications. The $1,035,589 award, spanning September 2024 to July 2026, aims to prepare the...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $349,325 Project Grant under CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research to Regennova, Inc., a small disadvantaged business in Durham, North Carolina. The grant supports the development of an orally-available, effective, and well-tolerated drug to treat autosomal dominant polycystic kidney disease (ADPKD), which affects over 350,000 Americans. The project aims to create and...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $350,000 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Katharos, Inc., a for-profit woman-owned business based in Denver, Colorado. The goal of this 1-year project is to develop and evaluate a novel extracorporeal device called the "PhosFilter" that can enhance phosphate removal from the blood of patients undergoing hemodialysis for...
This $675,480 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research to develop a novel therapeutic compound for treating chronic kidney disease (CKD). The awardee, Fibrotherapeutics Inc., is conducting preclinical studies to evaluate the efficacy, safety, and therapeutic index of a modified, water-soluble, orally-active peptide derived...
This Federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) totals $1,335,210 and is intended to support research into hydroxyproline dehydrogenase (HYPDH) inhibitors for the treatment of primary hyperoxaluria (PH). The research program, led by Wake Forest University Health Sciences, aims to optimize HYPDH inhibitor compounds through iterative design, synthesis,...
This Project Grant award of $929,940 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop a first-in-class dual agonist biologic for safely treating Type I and Type II diabetics experiencing impaired awareness of hypoglycemia (IAH). The award, effective September 1, 2024 through August 31, 2026, will support manufacturing, formulation, efficacy validation,...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Biotherapeutics, Inc. a $359,625 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports the development of next-generation, once-daily oral therapeutic candidates for the treatment of pre-diabetes and type 2 diabetes. Key research objectives include evaluating the therapeutic efficacy of the lead drug candidate on lipid metabolism, insulin...
The National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases awarded $3.6 million under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Anagram Therapeutics Inc. to develop a novel pancreatic enzyme replacement therapy. Specifically, Anagram will engineer lipase enzymes for improved stability against low pH and proteolytic degradation. This will allow for effective digestion of fats in both the stomach and small...